Cancer Aware · Patient & Family Guide

Biomarkers and Genetic Testing

Tumour biomarkers help select treatments and identify possible inherited risk. Genetic counselling explains when a finding may matter to relatives and what additional testing can establish.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 10 of 25

Four molecular groups — read alongside stage and histology
  1. POLEmut: qualifying pathogenic proofreading mutation
  2. MMRd: defective DNA mismatch repair
  3. p53abn: abnormal p53 biology after classifier integration
  4. NSMP: none of the other groups; grade and ER refine risk

What you will learn

  • Distinguish tumour testing from inherited, or germline, testing.
  • Understand MMR proteins, methylation, MSI, POLE, p53, ER/PR and HER2.
  • Know which findings need specialist interpretation.

MMR proteins and MSI

Immunohistochemistry is a laboratory stain that checks whether specific proteins are present in tumour cells. The four commonly assessed mismatch repair proteins are MLH1, PMS2, MSH2 and MSH6. Their loss patterns can guide further testing. MSI testing instead examines repeated DNA sequences for instability; it assesses a related consequence of defective repair.

MMR testing is broadly recommended in endometrial cancer because it informs molecular classification, systemic treatment options and Lynch screening. Discordant or technically uncertain results need pathology review, and sometimes a second method. Do not assume two apparently different reports necessarily mean the tumour changed.

MLH1 methylation and Lynch syndrome

When MLH1, often with PMS2, is lost, MLH1 promoter methylation testing can help identify an acquired silencing mechanism. Methylation commonly points toward a sporadic tumour. Unmethylated MLH1 loss, MSH2/MSH6 loss or isolated PMS2 loss usually warrants genetic counselling and consideration of germline testing.

A strong personal or family history can still justify genetics assessment despite methylation or retained MMR staining. Germline testing usually uses blood or saliva to look for inherited variants. A positive tumour test alone does not diagnose Lynch syndrome; two acquired tumour changes can sometimes explain repair deficiency without inherited disease.

Other classification and treatment tests

TestMain purposeImportant limitation
POLE sequencingIdentify qualifying proofreading-region mutationsUncertain variants do not establish the favourable group
p53 immunohistochemistryHelp identify p53-abnormal biologyPattern and technical controls matter
ER/PRAssess hormone-receptor expression; ER also refines NSMP riskPositivity does not guarantee hormonal response
HER2Identify selected cancers that may benefit from HER2-directed therapyAssay, score, histology and treatment indication must match
Broader sequencingLook for selected actionable alterations or trial optionsMany findings are not actionable

ER testing has a broader role in contemporary risk assessment, while PR may support selected hormonal-treatment decisions. HER2 testing is particularly relevant in appropriate advanced or recurrent serous, p53-abnormal or carcinosarcoma settings. Different HER2 medicines can require different eligibility thresholds; “HER2-low” is not interchangeable with an approved HER2 IHC 3+ tumour-agnostic indication.

What is routine and what is selective?

A complete molecular classification is encouraged where feasible, especially when it can change postoperative treatment. Access and local pathways differ; some low-risk situations use a selective POLE-testing strategy. Ask what information is missing and whether obtaining it would alter care. Universal large-panel sequencing is not a substitute for properly performed core pathology tests.

PD-L1 CPS, used in some other cancers, is not generally the selection requirement for the main endometrial chemo-immunotherapy or lenvatinib–pembrolizumab indications discussed in this guide. A negative PD-L1 result should not be interpreted in isolation as ruling out all immunotherapy options.

Questions, privacy and family implications

Before germline testing, discuss possible results, uncertain variants, family communication, costs and local privacy protections. A confirmed inherited pathogenic variant can guide testing of relatives; an uncertain variant should not automatically trigger preventive surgery. Ask for a written genetics summary and who will arrange any recommended colorectal or other surveillance.

Related chapters

References and review status

Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy